Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 16/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | DRD3 | P35462 | 10/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4914505 | 0.99 | DRD2 (0.44) | HTR1AHTR7DRD2HTR2ADRD3 | |
| SCHEMBL4919589 | 0.95 | HTR1A (0.47) | HTR1AHTR7DRD2HTR2ADRD3 | |
| SCHEMBL4913367 | 0.94 | DRD2 (0.48) | HTR1AHTR7DRD2HTR2ADRD3 | |
| SCHEMBL4918367 | 0.91 | DRD2 (0.47) | HTR1AHTR7DRD2HTR2ADRD3 | |
| SCHEMBL4917315 | 0.88 | DRD2 (0.45) | HTR1AHTR7DRD2HTR2ADRD3 | |
| Trifluoroacetic Acid SCHEMBL4906668 | 0.83 | DRD2 (0.55) | HTR1AHTR7DRD2HTR2ADRD3 | |
| Trifluoroacetic Acid SCHEMBL4917251 | 0.82 | DRD2 (0.55) | HTR1AHTR7DRD2HTR2ADRD3 | |
| SCHEMBL4918473 | 0.80 | KDM4E (0.49) | HTR1AHTR7DRD2DRD3DRD4 | |
| SCHEMBL4907586 | 0.79 | KDM4E (0.50) | HTR1AHTR7DRD2DRD3DRD4 | |
| SCHEMBL4907680 | 0.78 | DRD2 (0.49) | HTR1AHTR7DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | HTR1A 14/4885HTR7 184/4885DRD2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.